guest ::
| Home > Publications database > Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study. > print |
| Home > Publications database > Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study. > print |
| 001 | 286992 | ||
| 005 | 20241113141212.0 | ||
| 024 | 7 | _ | |a 10.1136/jitc-2023-007635 |2 doi |
| 024 | 7 | _ | |a pmid:38199608 |2 pmid |
| 024 | 7 | _ | |a altmetric:158274739 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-00109 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Penack, Olaf |0 0000-0003-4876-802X |b 0 |
| 245 | _ | _ | |a Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study. |
| 260 | _ | _ | |a London |c 2024 |b BioMed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1705044726_11435 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a We previously reported that the 'Endothelial Activation and Stress Index' (EASIX; ((creatinine×lactate dehydrogenase)÷thrombocytes)) measured before start of conditioning predicts mortality after allogeneic hematopoietic stem cell transplantation (alloSCT) when used as continuous score. For broad clinical implementation, a prospectively validated EASIX-pre cut-off is needed that defines a high-risk cohort and is easy to use.In the current study, we first performed a retrospective cohort analysis in n=2022 alloSCT recipients and identified an optimal cut-off for predicting non-relapse mortality (NRM) as EASIX-pre=3. For cut-off validation, we conducted a multicenter prospective study with inclusion of n=317 first alloSCTs from peripheral blood stem cell in adult patients with acute leukemia, lymphoma or myelodysplastic syndrome/myeloproliferative neoplasms in the European Society for Blood and Marrow Transplantation network.Twenty-three % (n=74) of alloSCT recipients had EASIX-pre ≥3 taken before conditioning. NRM at 2 years was 31.1% in the high EASIX group versus 11.5% in the low EASIX group (p<0.001). Patients with high EASIX-pre also had worse 2 years overall survival (51.6% vs 70.9%; p=0.002). We were able to validate the cut-off and found that EASIX ≥3 was associated with more than twofold increased risk for NRM in multivariate analysis (HR=2.18, 95% CI 1.2 to 3.94; p=0.01). No statistically significant difference could be observed for the incidence of relapse.The results of this study provide a prospectively validated standard laboratory biomarker index to estimate the transplant-related mortality risk after alloSCT. EASIX ≥3 taken before conditioning identifies a population of alloSCT recipients who have a more than twofold increased risk of treatment-related mortality. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Hematologic Neoplasms |2 Other |
| 650 | _ | 7 | |a Immunotherapy |2 Other |
| 650 | _ | 7 | |a Inflammation |2 Other |
| 700 | 1 | _ | |a Luft, Thomas |b 1 |
| 700 | 1 | _ | |a Peczynski, Christophe |b 2 |
| 700 | 1 | _ | |a Benner, Axel |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 3 |u dkfz |
| 700 | 1 | _ | |a Sica, Simona |b 4 |
| 700 | 1 | _ | |a Arat, Mutlu |b 5 |
| 700 | 1 | _ | |a Itäla-Remes, Maija |b 6 |
| 700 | 1 | _ | |a Corral, Lucia López |b 7 |
| 700 | 1 | _ | |a Schaap, Nicolaas P M |b 8 |
| 700 | 1 | _ | |a Karas, Michal |b 9 |
| 700 | 1 | _ | |a Raida, Ludek |b 10 |
| 700 | 1 | _ | |a Schroeder, Thomas |b 11 |
| 700 | 1 | _ | |a Dreger, Peter |b 12 |
| 700 | 1 | _ | |a Metafuni, Elisabetta |b 13 |
| 700 | 1 | _ | |a Ozcelik, Tulay |b 14 |
| 700 | 1 | _ | |a Sandmaier, Brenda M |b 15 |
| 700 | 1 | _ | |a Kordelas, Lambros |b 16 |
| 700 | 1 | _ | |a Moiseev, Ivan |b 17 |
| 700 | 1 | _ | |a Schoemans, Hélène |b 18 |
| 700 | 1 | _ | |a Koenecke, Christian |b 19 |
| 700 | 1 | _ | |a Basak, Grzegorz W |b 20 |
| 700 | 1 | _ | |a Peric, Zinaida |b 21 |
| 773 | _ | _ | |a 10.1136/jitc-2023-007635 |g Vol. 12, no. 1, p. e007635 - |0 PERI:(DE-600)2719863-7 |n 1 |p e007635 |t Journal for ImmunoTherapy of Cancer |v 12 |y 2024 |x 2051-1426 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/286992/files/e007635.full.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/286992/files/e007635.full.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:286992 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J IMMUNOTHER CANCER : 2022 |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-05-02T08:46:44Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-05-02T08:46:44Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-05-02T08:46:44Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-19 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-19 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-19 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b J IMMUNOTHER CANCER : 2022 |d 2023-08-19 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-08-19 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-08-19 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|